Oramed Pharmaceuticals
ORMP
25 hedge funds and large institutions have $1.84M invested in Oramed Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.
1,484% more call options, than puts
Call options by funds: $1.55M | Put options by funds: $98K
41% more capital invested
Capital invested by funds: $1.31M → $1.84M (+$536K)
0% more funds holding
Funds holding: 25 → 25 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$295K |
| 2 |
Millennium Management
New York
|
+$143K |
| 3 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
+$72K |
| 4 |
FANJ
Financial Architects (New Jersey)
Marlton,
New Jersey
|
+$29.4K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$29.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSBC Holdings
London,
United Kingdom
|
-$100K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$85.4K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
-$73.7K |
| 4 |
GIM
Greylin Investment Management
Orange,
Virginia
|
-$69K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$13.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GIM
26
Greylin Investment Management
Orange,
Virginia
| – | -$69K | -10,300 | Closed |
|
|
27
Group One Trading
Chicago,
Illinois
| – | -$85.4K | -10,030 | Closed |
|
|
DLHL
28
Donald L. Hagan LLC
Sarasota,
Florida
| – | -$7K | -1,000 | Closed |
|
|
WA
29
WealthTrust-Arizona
Scottsdale,
Arizona
| – | -$3K | -500 | Closed |
|
30
JP Morgan Chase
New York
| – | +$85 | +10 | New |
|
ORMP Hedge Fund Activity: Q2 2016 in Review
25 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2016, worth a combined $1.84M — up 41% from $1.31M a quarter earlier.
Fund positioning in ORMP was balanced in Q2 2016: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $295K. The largest seller was HSBC Holdings, exiting entirely with an estimated $100K sold.
- 25 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $1.84M of Oramed Pharmaceuticals stock for Q2 2016, up 41% quarter-over-quarter.
- 5 funds opened new Oramed Pharmaceuticals positions in Q2 2016 and 5 closed out, a net change of 0 holders.
- The largest Oramed Pharmaceuticals buyer in Q2 2016 was Morgan Stanley, an estimated $295K added.
- The largest Oramed Pharmaceuticals seller in Q2 2016 was HSBC Holdings, an estimated $100K sold.
Based on aggregated 13F filings for Q2 2016.